 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- ADL5747 / Merck (MSD)
Enrollment change, Trial termination, Trial primary completion date: Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia (clinicaltrials.gov) - Jul 9, 2015
P2a, N=41, Terminated, Sponsor: Cubist Pharmaceuticals
N=92 --> 41 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2011 --> Dec 2010
- PF-4856884 / Pfizer
Enrollment change: A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Mar 11, 2015
P2, N=0, Withdrawn, Sponsor: Pfizer
N=92 --> 41 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2011 --> Dec 2010 N=50 --> 0
- Inlyta (axitinib) / Pfizer, PF-4856884 / Pfizer
Trial termination, Combination therapy, Metastases: PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Jan 17, 2013
P2, N=18, Terminated, Sponsor: Pfizer
N=50 --> 0 Active, not recruiting --> Terminated; See termination reason in detailed description.
- | PF-04856883 / Pfizer
Trial completion: A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers (clinicaltrials.gov) - Jan 16, 2013
P1, N=49, Completed, Sponsor: Pfizer
Active, not recruiting --> Terminated; See termination reason in detailed description. Active, not recruiting --> Completed
- | PF-04856883 / Pfizer
New P1 trial: A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers (clinicaltrials.gov) - Jul 9, 2012
P1, N=49, Completed, Sponsor: Pfizer
- ||| PF-04856883 / Pfizer
Trial completion: Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females (clinicaltrials.gov) - May 14, 2012
P1, N=84, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Inlyta (axitinib) / Pfizer, PF-4856884 / Pfizer
New P2 trial, Combination therapy, Metastases: PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Sep 25, 2011
P2, N=18, Terminated, Sponsor: Pfizer